These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21998010)

  • 1. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
    FitzGerald DJ; Wayne AS; Kreitman RJ; Pastan I
    Cancer Res; 2011 Oct; 71(20):6300-9. PubMed ID: 21998010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-homing toxins.
    Ng HC; Khoo HE
    Curr Pharm Des; 2002; 8(22):1973-85. PubMed ID: 12171523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotoxins for leukemia.
    Wayne AS; Fitzgerald DJ; Kreitman RJ; Pastan I
    Blood; 2014 Apr; 123(16):2470-7. PubMed ID: 24578503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotoxins in the treatment of refractory hairy cell leukemia.
    Kreitman RJ; Pastan I
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.
    Frankel AE; Sievers EL; Scheinberg DA
    Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates.
    Hollander I; Kunz A; Hamann PR
    Bioconjug Chem; 2008 Jan; 19(1):358-61. PubMed ID: 17994681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
    Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
    Alderson RF; Kreitman RJ; Chen T; Yeung P; Herbst R; Fox JA; Pastan I
    Clin Cancer Res; 2009 Feb; 15(3):832-9. PubMed ID: 19188153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotoxins in the treatment of hematologic malignancies.
    Kreitman RJ; Pastan I
    Curr Drug Targets; 2006 Oct; 7(10):1301-11. PubMed ID: 17073592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
    Du X; Ho M; Pastan I
    J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA approves antibody-directed cytotoxic agent for acute myeloid leukemia.
    Miller JL
    Am J Health Syst Pharm; 2000 Jul; 57(13):1202, 1204. PubMed ID: 10902059
    [No Abstract]   [Full Text] [Related]  

  • 13. Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide.
    Marks AJ; Cooper MS; Anderson RJ; Orchard KH; Hale G; North JM; Ganeshaguru K; Steele AJ; Mehta AB; Lowdell MW; Wickremasinghe RG
    Cancer Res; 2005 Mar; 65(6):2373-7. PubMed ID: 15781652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
    Kreitman RJ
    BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
    Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
    Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patents on immunotoxins and chimeric toxins for the treatment of cancer.
    Bachran C; Sutherland M; Bachran D; Fuchs H
    Recent Pat Drug Deliv Formul; 2007; 1(2):105-15. PubMed ID: 19075878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
    Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies.
    Keppler-Hafkemeyer A; Kreitman RJ; Pastan I
    Int J Cancer; 2000 Jul; 87(1):86-94. PubMed ID: 10861457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
    Schwemmlein M; Peipp M; Barbin K; Saul D; Stockmeyer B; Repp R; Birkmann J; Oduncu F; Emmerich B; Fey GH
    Br J Haematol; 2006 Apr; 133(2):141-51. PubMed ID: 16611304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic monoclonal antibodies in onco-hematology].
    Cartron G; Rossi JF
    Med Sci (Paris); 2009 Dec; 25(12):1085-9. PubMed ID: 20035683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.